/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of.
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events at 30 days with use of AMDS in Acute DeBakey Type I Dissections.